The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Wogonin suppresses inflammatory response and maintains intestinal barrier function via TLR4-MyD88-TAK1-mediated NF-κB pathway in vitro
Abstract
Aims and objective Wogonin has multiple pharmacological effects, including anti-inflammatory effects. Here, we hypothesize that wogonin can protect intestinal barrier function in lipopolysaccharide (LPS)-induced Caco-2 cells, which is an in vitro model of intestinal inflammation.Methods We measured intestinal barrier function in LPS-induced Caco-2 cells by using transepithelial electrical resistance (TEER) and transport of fluorescent markers. A quantitative (q) RT-PCR and immunofluorescent staining analysis was used to detect the expression of tight junction proteins (claudin-1 and ZO-1) in LPS-induced Caco-2 cells. We measured inflammatory molecules in LPS-induced Caco-2 cells using ELISA and qRT-PCR. In addition, the expression of TLR4, MyD88 and TAK1 and their interaction, and NF-κB activity in LPS-induced Caco-2 cells were investigated by western blot analysis and immune-precipitation.Results We found that exposing Caco-2 cells to wogonin (10 and 50 μM for 24 h) attenuated the LPS-induced changes in TEER and transport of fluorescent markers. In addition, wogonin suppressed LPS-induced down-regulation of tight junction proteins (claudin-1 and ZO-1). Furthermore, LPS-induced up-regulation of inflammatory mediators, including interleukin (IL)-1β, IL-6 and IL-8, cyclooxygenase-2 (COX-2), inducible nitric oxide synthases (iNOS) were reduced after being pre-treated with wogonin. Moreover, wogonin not only inhibited the expression of TLR4, MyD88 and TAK1 and the interaction between these molecules, but also reduced NF-κB translocation to nucleus and its DNA-binding activity in LPS-induced Caco-2 cells.Conclusion Our results suggested that pre-treatment with wogonin could attenuate the TLR4-mediated inflammatory response and maintain intestinal barrier function in LPS-induced Caco-2 cells, thus might be a potential therapy for treating IBD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, wogonin suppresses the inflammatory response and maintains intestinal barrier function via the TLR4-MyD88-TAK1 (TGF-β activated kinase 1)-NF-κB (nuclear factor-kappa B) pathway in Caco-2 cells.160”
From Regulation of Intestinal Barrier Function by Microbial Metabolites (2021) · cites this paper as [160]
Citations
Cites
Unravelling the pathogenesis of inflammatory bowel disease
Xavier, R. J., & Podolsky, D. K. (2007) · Nature · doi:10.1038/nature06005 · Cited by 4,364
IL-1β Causes an Increase in Intestinal Epithelial Tight Junction Permeability
Al-Sadi, R. M., & Ma, T. Y. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4641 · Cited by 601
Su, L., Shen, L., Clayburgh, D. R., Nalle, S. C., Sullivan, E. A., Meddings, J. B., Abraham, C., & Turner, J. R. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.10.081 · Cited by 455
Lee, H., Kim, Y. O., Kim, H., Kim, S. Y., Noh, H. S., Kang, S. S., Cho, G. J., Choi, W. S., & Suk, K. (2003) · The FASEB Journal · doi:10.1096/fj.03-0057fje · Cited by 280
Huang, W., Lee, A., & Yang, C.-H. (2006) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.50698 · Cited by 230
Chi, Y. S., Lim, H. A., Park, H., & Kim, H. P. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00463-5 · Cited by 212
Bhattacharyya, S., Gill, R. K., Chen, M. L., Zhang, F., Linhardt, R. J., Dudeja, P. K., & Tobacman, J. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708833200 · Cited by 170
Therapeutic Potential of Wogonin: A Naturally Occurring Flavonoid
Tai, M. C., Tsang, S. Y., Chang, L. Y. F., & Xue, H. (2005) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2005.tb00266.x · Cited by 154
Stahl, M., Ries, J., Vermeulen, J., Yang, H. Y., Sham, H. P., Crowley, S. M., Badayeva, Y., Turvey, S. E., Gaynor, E. C., Li, X., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004264 · Cited by 117
Lin, Y., Huang, D.-Y., Chu, C., Lin, Y., & Lin, W. (2013) · Science Signaling · doi:10.1126/scisignal.2003973 · Cited by 92
Cited by
Sorted by citations
Regulation of Intestinal Barrier Function by Microbial Metabolites
Ghosh, S., Whitley, C. S., Haribabu, B., & Jala, V. R. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.02.007 · Cited by 835
Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease
Violi, F., Cammisotto, V., Bartimoccia, S., Pignatelli, P., Carnevale, R., & Nocella, C. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00737-2 · Cited by 400
Liao, H., Ye, J., Gao, L., & Liu, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110917 · Cited by 348
Gil‐Cardoso, K., Ginés, I., Pinent, M., Ardèvol, A., Blay, M., & Terra, X. (2016) · Nutrition Research Reviews · doi:10.1017/s0954422416000159 · Cited by 236
Therapeutic potential of flavonoids in inflammatory bowel disease: A comprehensive review
Salaritabar, A., Darvishi, B., Hadjiakhoondi, F., Manayi, A., Sureda, A., Nabavi, S. F., Fitzpatrick, L. R., Nabavi, S. M., & Bishayee, A. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i28.5097 · Cited by 203
Metadata
- Authors
- Wang, W., Xia, T., & Yu, X.
- Affiliations
- Jiangyin People's Hospital (CN)
- ORCID
- Wang, Wenping
- Venue
- Inflammation Research
- Published
- 2015-04-28
- Volume
- 64
- Issue
- 6
- Pages
- 423-431
- ISSN
- 1023-3830 (ISSN-L)
- 1420-908X
- OpenAlex
- W2079479624
- Cited by
- 110
- References
- 27
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 9 · 2023: 10 · 2022: 14 · 2021: 9 · 2020: 9 · 2019: 5 · 2018: 9 · 2017: 13 · 2016: 12 · 2015: 2
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Inflammation Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Flavonoids in Medical Research
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- wogonin, intestinal barrier function, intestinal inflammation, TLR4, MyD88, TAK1, NF-κB signaling, lipopolysaccharide, Caco-2 cells, tight junction proteins, claudin-1, ZO-1, inflammatory cytokines, cyclooxygenase-2, inducible nitric oxide synthase, inflammatory bowel disease
- MeSH terms
- MAP Kinase Kinase Kinase 7, Anti-Inflammatory Agents, Antioxidants, Biological Transport, Active, Humans, Interleukins, Intestines, Signal Transduction, NF-kappa B, Electric Impedance, Inflammation Mediators, Caco-2 Cells, MAP Kinase Kinase Kinases, Flavanones, Toll-Like Receptor 4, Myeloid Differentiation Factor 88, Claudin-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
